Larotrectinib for treating NTRK fusion-positive advanced solid tumours (MA review of TA630) [ID6292] Draft guidance Technology appraisal guidance 24 April 2026 Donanemab for treating mild cognitive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results